September 2022

08 Sep Results from APOLLO-B Phase 3 Study of Patisiran Presented at ISA

During a late-breaker session at the 18^th International Symposium on Amyloidosis, we presented results from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. Read the press release Maurer, et al. “Primary Results from APOLLO-B, a Phase 3 Study of Patisiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy”

29 Aug New Results from Phase 2 Study of Investigational Cemdisiran Presented at EMCHD

During the 18th European Meeting on Complement in Human Disease (EMCHD), taking place August 26-28, 2022, we presented new results from the Phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway that is being developed in collaboration...

02 Aug ILLUMINATE-B Phase 3 Results for OXLUMO® (lumasiran) Published in Pediatric Nephrology

Results from the 12-month analysis of the ongoing ILLUMINATE-B Phase 3 open-label pediatric study of OXLUMO® (lumasiran) in patients less than six years of age with primary hyperoxaluria type 1 (PH1) were published online in Pediatric Nephrology. Read the paper in the Pediatric Nephrology...

23 Jul HELIOS-A 18-Month Phase 3 Results for AMVUTTRA™ (vutrisiran) Published in Amyloid

Eighteen-month efficacy and safety results from the HELIOS-A Phase 3 study of AMVUTTRA™ (vutrisiran), an RNAi therapeutic recently approved in the U.S. for adults with the polyneuropathy of hereditary ATTR (hATTR) amyloidosis, were published in Amyloid. Read the paper in Amyloid...

20 Jul ILLUMINATE-C Phase 3 Results for Lumasiran Published in American Journal of Kidney Diseases

Results from the six-month primary analysis of the ongoing ILLUMINATE-C Phase 3 study of lumasiran in patients of all ages with primary hyperoxaluria type 1 (PH1) and advanced kidney disease were published online in the American Journal of Kidney Diseases. Read the paper in the American...

24 May New Results from ILLUMINATE-C Phase 3 Study of Lumasiran Presented at ERA-EDTA

New results from the six-month primary analysis of the ILLUMINATE-C Phase 3 open-label study of lumasiran in patients of all ages with advanced primary hyperoxaluria type 1 (PH1) were presented at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) International Congress (May 19-22, 2022). Findings...

23 May New 18-Month Exploratory Cardiac Results from HELIOS-A Phase 3 Study of Vutrisiran

During the annual Heart Failure congress of the Heart Failure Association of the European Society of Cardiology, taking place May 21-24, 2022, we presented new 18-month results from the exploratory cardiac endpoints in the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in...

16 May News Results from HELIOS-A Phase 3 Study of Vutrisiran Presented at PNS 2022

New results from the HELIOS-A study of vutrisiran, an investigational RNAi therapeutic, in hereditary transthyretin-mediated (hATTR) amyloidosis patients with polyneuropathy, were presented during the Peripheral Nerve Society (PNS) 2022 Annual Meeting, taking place May 14-17, 2022. Ajroud-Driss, et al. “HELIOS-A: Impact of Vutrisiran on Quality of...

11 May Preclinical Results on Alnylam’s Novel C16 Conjugate Technology for Delivery of siRNAs to the Central Nervous System Presented at TIDES USA 2022 Meeting

New results on Alnylam’s platform advancements enabling delivery of therapeutic short interfering RNAs (siRNAs) to the central nervous system (CNS) were presented at the TIDES USA, Oligonucleotide & Peptide Therapeutics 2022 Meeting being held in Boston on May 9-12. Additional preclinical data were presented on...

25 Apr New Results from 12M Analysis of ILLUMINATE-B Phase 3 Study of OXLUMO® (lumasiran) Presented at PAS 2022

New results from the 12-month analysis of the ongoing ILLUMINATE-B Phase 3 open-label pediatric study of OXLUMO® (lumasiran) in patients less than six years of age with primary hyperoxaluria type 1 (PH1) were presented at the Pediatric Academic Societies (PAS) 2022 Meeting (April 21-25, 2022). Michael,...